Vax Safety Data Sheet From Pfizer.com

https://safetydatasheets.pfizer.com...YsQgKm3T3URdZ9xTuKeQL6LNFIVE6GYOOr2xc1NE_hQ70

DownloadSingleFile (pfizer.com)

 

SAFETY DATA SHEET Revision date 16-Nov-2020 Version 1.02 Page 1 / 10 Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING 1.1. Product identifier Product Name Pfizer-BioNTech COVID-19 Vaccine Product Code(s) PF00092 Synonyms PF-07302048 containing PF-07305885 (BNT162b2); CorVAC Containing PF-07305885 (BNT162b2) ; CoVVAC Containing PF-07305885 (BNT162b2); COVID Vaccine Containing PF-07305885 (BNT162b2); COVID-19 Vaccine Containing PF-07305885 (BNT162b2) Trade Name: Not applicable Compound Number PF-07302048 Item Code H000022941: H000023057 Chemical Family: Lipid Nanoparticles containing PF-07305885 (BNT162b2) and Lipids 1.2. Relevant identified uses of the substance or mixture and uses advised against Recommended Use Pharmaceutical product 1.3. Details of the supplier of the safety data sheet 1.4. Emergency telephone number Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887 E-mail address pfizer-MSDS@pfizer.com Section 2: HAZARDS IDENTIFICATION 2.1. Classification of the substance or mixture Not classified as hazardous 2.2. Label elements Signal word Not classified Hazard statements Not classified in accordance with international standards for workplace safety. 2.3. Other hazards Other hazards An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8). Pfizer Inc 235 East 42nd Street New York, New York 10017 1-800-879-3477 Pfizer Ltd Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161 _____________________________________________________________________________________________ PF00092 SAFETY DATA SHEET _____________________________________________________________________________________________ Product Name Pfizer-BioNTech COVID-19 Vaccine Page 2 / 10 Revision date 16-Nov-2020 Version 1.02 Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace. Section 3: COMPOSITION/INFORMATION ON INGREDIENTS 3.1 Substances NonHazardous Chemical Name EC No CAS No Weight-% Classification according to Regulation (EC) No. 1272/2008 [CLP] REACH Registration Number Water 231-791-2 7732-18-5 * Not Listed Sucrose 200-334-9 57-50-1 < 10 Not Listed SODIUM CHLORIDE 231-598-3 7647-14-5 < 10 Not Listed ALC-0315 Not Listed NOT ASSIGNED < 2 Not Listed Potassium phosphate 231-913-4 7778-77-0 < 1 Not Listed POTASSIUM CHLORIDE 231-211-8 7447-40-7 < 1 Not Listed PF-07305885 Not Listed NOT ASSIGNED 42 g/m3 Rat Oral LD 50 3 g/kg Vapor pressure No data available Vapor density No data available Relative density No data available Water solubility No data available Solubility(ies) No data available Autoignition temperature No data available Decomposition temperature No data available Kinematic viscosity No data available Dynamic viscosity _____________________________________________________________________________________________ PF00092 No data available SAFETY DATA SHEET _____________________________________________________________________________________________ Product Name Pfizer-BioNTech COVID-19 Vaccine Page 7 / 10 Revision date 16-Nov-2020 Version 1.02 Mouse Oral LD 50 4 g/kg Rabbit Dermal LD 50 > 10 g/kg POTASSIUM CHLORIDE Rat Oral LD50 2600 mg/kg Potassium phosphate Rat Oral LD50 3200 mg/kg Rabbit Dermal LC50 > 4640 mg/kg Chemical Name Oral LD50 Dermal LD50 Inhalation LC50 Water > 90 mL/kg ( Rat ) - - Sucrose = 29700 mg/kg ( Rat ) - - SODIUM CHLORIDE = 3 g/kg ( Rat ) - > 42 g/m3 ( Rat ) 1 h Potassium phosphate = 3200 mg/kg ( Rat ) - - POTASSIUM CHLORIDE = 2600 mg/kg ( Rat ) - - Irritation / Sensitization: (Study Type, Species, Severity) SODIUM CHLORIDE Skin Irritation Rabbit Mild Eye Irritation Rabbit Mild POTASSIUM CHLORIDE Eye Irritation Rabbit Mild Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ) PF-07302048 4 Week(s) Rat Intramuscular * 10 µg LOAEL Skin, Blood forming organs, Blood, Skeletal muscle, Lymphoid tissue, Spleen Repeated Dose Toxicity Comments: PF-07302048: * Doses were administered once a week. Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s)) Potassium phosphate Reproductive & Fertility Rat No route specified 282 mg/kg/day NOAEL No evidence of impaired fertility or harm to the fetus Reproductive & Fertility Mouse No route specified 320 mg/kg/day NOAEL No evidence of impaired fertility or harm to the fetus Genetic Toxicity: (Study Type, Cell Type/Organism, Result) Potassium phosphate Bacterial Mutagenicity (Ames) Salmonella Negative Carcinogenicity See below Cholesterol IARC Group 3 (Not Classifiable) Section 12: ECOLOGICAL INFORMATION Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided. 12.1. Toxicity Aquatic Toxicity: (Species, Method, End Point, Duration, Result) POTASSIUM CHLORIDE _____________________________________________________________________________________________ PF00092 Gambusia affinis (Mosquitofish) LC50 96 hours 920 mg/l SAFETY DATA SHEET _____________________________________________________________________________________________ Product Name Pfizer-BioNTech COVID-19 Vaccine Page 8 / 10 Revision date 16-Nov-2020 Version 1.02 Lepomis macrochirus (Bluegill Sunfish) LC50 96 hours 2010 mg/L Daphnia Magna (Water Flea) EC50 48 hours 825 mg/l Scenedesmus subspicatus (Green Alga) EC50 72 Hours 2500 mg/L 12.2. Persistence and degradability Persistence and degradability No information available. 12.3. Bioaccumulative potential Bioaccumulation No information available. 12.4. Mobility in soil Mobility in soil No information available. 12.5. Results of PBT and vPvB assessment PBT and vPvB assessment No information available. Chemical Name PBT and vPvB assessment SODIUM CHLORIDE The substance is not PBT / vPvB PBT assessment does not apply Potassium phosphate The substance is not PBT / vPvB PBT assessment does not apply POTASSIUM CHLORIDE The substance is not PBT / vPvB PBT assessment does not apply Cholesterol The substance is not PBT / vPvB 12.6. Other adverse effects Other adverse effects No information available. Section 13: DISPOSAL CONSIDERATIONS 13.1. Waste treatment methods Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater. Section 14: TRANSPORT INFORMATION The following refers to all modes of transportation unless specified below. Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations. _____________________________________________________________________________________________ PF00092 SAFETY DATA SHEET _____________________________________________________________________________________________ Product Name Pfizer-BioNTech COVID-19 Vaccine Page 9 / 10 Revision date 16-Nov-2020 Version 1.02 Section 15: REGULATORY INFORMATION 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture Water CERCLA/SARA Section 313 de minimus % Not Listed California Proposition 65 Not Listed TSCA Present EINECS 231-791-2 AICS Present Sucrose CERCLA/SARA Section 313 de minimus % Not Listed California Proposition 65 Not Listed TSCA Present EINECS 200-334-9 AICS Present SODIUM CHLORIDE CERCLA/SARA Section 313 de minimus % Not Listed California Proposition 65 Not Listed TSCA Present EINECS 231-598-3 AICS Present ALC-0315 CERCLA/SARA Section 313 de minimus % Not Listed California Proposition 65 Not Listed EINECS Not Listed Potassium phosphate CERCLA/SARA Section 313 de minimus % Not Listed California Proposition 65 Not Listed TSCA Present EINECS 231-913-4 AICS Present POTASSIUM CHLORIDE CERCLA/SARA Section 313 de minimus % Not Listed California Proposition 65 Not Listed TSCA Present EINECS 231-211-8 AICS Present Standard for Uniform Scheduling of Medicines and Poisons (SUSMP) Schedule 4 PF-07305885 CERCLA/SARA Section 313 de minimus % Not Listed California Proposition 65 Not Listed EINECS Not Listed PF-07302048 CERCLA/SARA Section 313 de minimus % Not Listed California Proposition 65 Not Listed EINECS Not Listed PEGA / ALC-0159 CERCLA/SARA Section 313 de minimus % Not Listed California Proposition 65 Not Listed EINECS Not Listed Disodium phosphate dihydrate CERCLA/SARA Section 313 de minimus % Not Listed California Proposition 65 Not Listed EINECS Not Listed AICS Present Standard for Uniform Scheduling of Medicines and Schedule 5 _____________________________________________________________________________________________ PF00092 SAFETY DATA SHEET _____________________________________________________________________________________________ Product Name Pfizer-BioNTech COVID-19 Vaccine Page 10 / 10 Revision date 16-Nov-2020 Version 1.02 Poisons (SUSMP) Cholesterol CERCLA/SARA Section 313 de minimus % Not Listed California Proposition 65 Not Listed TSCA Present EINECS 200-353-2 AICS Present Standard for Uniform Scheduling of Medicines and Poisons (SUSMP) Schedule 4 1,2-Distearoyl-sn-glycero-3-phosphocholine CERCLA/SARA Section 313 de minimus % Not Listed California Proposition 65 Not Listed EINECS 212-440-2 15.2. Chemical safety assessment Chemical Safety Report No information available Section 16: OTHER INFORMATION Key or legend to abbreviations and acronyms used in the safety data sheet Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information. Reason for revision Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Revision date 16-Nov-2020 Prepared By Product Stewardship Hazard Communication Pfizer Global Environment, Health, and Safety Operations Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time. _____________________________________________________________________________________________ PF00092

 

Find out what the government is recommending we inject into our bodies.
Here is the list of ingredients in the Pfizer vaccine
(including the ingredients they have not listed on their vaccine package insert).
Further information to follow.

Mary C. Davis
Helping bring well-being to people's lives, organizations and businesses! https://www.anamturas.com

(6) Mary C. Davis | Facebook

https://safetydatasheets.pfizer.com...YsQgKm3T3URdZ9xTuKeQL6LNFIVE6GYOOr2xc1NE_hQ70
DownloadSingleFile (pfizer.com)

 

First COVID-19 vaccinations

administered in Canada,

kicking off massive campaign

---

First COVID-19 vaccinations administered in Canada, kicking off massive campaign


TORONTO — A long-term care resident in Quebec and a nursing home worker in Ontario
received Canada's first COVID-19 vaccinations on Monday,

kicking off the largest immunization campaign in the country's history.

© Provided by The Canadian Press

The shots from Pfizer were administered in Quebec City and Toronto
within half an hour of each other, creating some confusion about which province
could lay claim to being the first in the country to hand out the doses.

“What we witnessed today is a massive step forward in the fight against this deadly virus,"
said Ontario Premier Doug Ford, who thanked the Toronto hospital network
that administered his province's first vaccines.

"Thanks to them we were the first in Canada and one of the first in North America to administer this vaccine."

In Quebec, the province's health minister said 89-year-old Gisele Levesque
received her vaccination at 11:30 a.m. ET at the Saint-Antoine long-term care home
in the provincial capital, making her the first in Canada to get the shot.

But that was only announced after Anita Quidangen, a Toronto personal support worker,
received her shot during a live broadcast around noon.

Leaders in both provinces said the roll out of the shots marked a historic day.

"This is a watershed moment - the beginning of the end of this terrible pandemic," Ford said in a statement.

"The light at the end of the tunnel grows brighter every day, but we must remain on our guard."

Quebec Health Minister Christian Dube said it was "a very, very big day" for the province.

Officials said they would be vaccinating residents and staff at the Quebec City
long-term care home and at the Maimonides Geriatric Centre in Montreal
after receiving a shipment of the vaccine Sunday night.

In Toronto, Quidangen, a long-time employee of the Rekai Centre nursing home,
received the vaccine to applause from staff from the University Health Network.

Cheers erupted as she bumped elbows with hospital executives moments later.

She was among a group of five nursing-home workers
who were given the first few shots of the vaccine in Ontario.

"It's an honour, thank you very much," she said. "I'll continue to do my job as a PSW"

Ford praised Quindangen and the other workers who got the shot for their dedication to their jobs.

Ontario received 6,000 doses of Pfizer's COVID-19 vaccine on Sunday.

The government plans to give them to approximately 2,500 health-care workers.

Half the shots will be administered this week and the other half
will be intentionally held back to give the same workers a required second dose 21 days later.

The vaccines in Toronto were given at the Michener Institute, which is run by the University Health Network.

The president of the network, Kevin Smith, called the administration of the first vaccines a victory for science.

"Today, really, we turned the corner," Smith said. "I like to say this is the shot that will be heard around the world."

Ontario has said health-care workers, long-term care residents,
and their caregivers will be among the first to receive the vaccine.

Adults in Indigenous communities, residents of retirement homes,
and recipients of chronic home health-care will also be priority groups.

The province said it will also be prioritizing the distribution of the vaccine
in regions with the highest rates of COVID-19.

The government has said, however, that the vaccine isn't expected
to be more broadly available to the general public until April.

Retired Gen. Rick Hillier, who is leading the province’s vaccine task force,
says an additional 90,000 doses of the Pfizer vaccine are expected to arrive later this month.

Those doses will be provided to 14 hospitals in COVID-19 hot spots.

Hillier has said Ontario also expects to receive between 30,000 and 85,000 doses
of the Moderna vaccine by the new year, pending its approval by Health Canada.

The province expects to receive 2.4 million doses
– allowing it to vaccinate 1.2 million people
– during the first three months of 2021.

Ontario reported 1,940 new cases of COVID-19 on Monday, and 23 new deaths due to the virus.

Quebec reported 1,620 new COVID-19 cases on Monday and 25 more deaths linked to the novel coronavirus.

This report by The Canadian Press was first published Dec. 14, 2020.

The Canadian Press


https://www.msn.com/en-ca/news/cana...ff-massive-campaign/ar-BB1bVc8R?ocid=msedgntp
First COVID-19 vaccinations administered in Canada, kicking off massive campaign (msn.com)